Alzamend Neuro, Inc. (ALZN) stock
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
$1.13−0.05 (-4.24%)
Close on Nov 17, 2026Market cap $5.45MP/E –Yield –
Alzamend Neuro ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Alzamend Neuro
Alzamend Neuro has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?